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http://dx.doi.org/10.1016/j.gmbhs.20Abstract A weighted enzymatic chip array (WEnCA) can detect the gene expression of circu-
lating tumor cells (CTCs) in the peripheral blood of patients with colorectal cancer (CRC). In this
study, we used a reagent kit, the GeneCling CRC Enzymatic Gene Chip Detection Kit, which was
specifically developed for the WEnCA operation platform to analyze the expression of 31 CRC-
related genes of CTCs in the peripheral blood of 30 CRC patients. We moreover evaluated the
expression of the genes by simultaneously using real-time quantitative polymerase chain reaction
(RT-QPCR). The results showed the overexpression rate of nine genesdDVL1, ELAVL4, CHRNB1,
UBE2C, PSAT1, CEA, PTTG1, KRT19, and hTERTdwas greater than 90% in the CRC patients. This
is concordant with the results of the original WEnCA operation procedure. Linear regression anal-
ysis demonstrateda high correlation (rZ 0.901;p< 0.0001) between theexperimental data of the
detection kit and RT-QPCR. The GeneCling CRC Enzymatic Gene Chip Detection Kit is easy, fast,
and convenient to operate for detecting gene expression of CTCs from peripheral blood. However,Medical Research, Fooyin University Hospital, Number 5, Jhongshan Road, Donggang Township,
l.com (F.-Y. Chung).
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88 C.-H. Wu et al.the correlation between the differential expression and the clinicopathological features of the 31
CRC-related genes needs further investigation to verify the clinical value.
Copyrightª 2013, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier Taiwan
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Colorectal cancer (CRC) is the most common tumor in the
world.1 In Taiwan, CRC is one of the most frequent malig-
nancies and the third major cause of cancer death.2 The
diagnosis and surgical treatments for CRC have improved in
recent years; however, the patient survival rate remains
low. This is primarily because of the consistently poor
prognosis of patients who have an advanced stage of
CRC.3,4 Approximately 40e50% of CRC patients who un-
dergo a supposedly curative resection subsequently
develop metastatic disease and die of their disease within 5
years.5,6 Therefore, early diagnosis is imperative for
obtaining a better therapeutic outcome and prognosis.
Recent studies have shown that detecting the molecular
markers of circulating tumor cells (CTCs) in the peripheral
blood of CRC patients may be useful for cancer diagnosis,
prognosis assessment, or postoperative follow-up assess-
ments.7 Common techniques used for detecting the mo-
lecular markers of CTCs are polymerase chain reaction
(PCR), reverse transcriptaseePCR (RT-PCR), or real-time
quantitative PCR (RT-QPCR) assays. Analyzing a single
biomarker only provides limited sensitivity and specificity.
The combination of multiple biomarkers may be able to
improve diagnosis in patients.8,9 The weighted enzymatic
chip array (WEnCA) platform that we developed in our
previous study can detect CTCs in the peripheral blood of
CRC patients. We also demonstrated a high correlation
between the RT-QPCR and the WEnCA method in detecting
CTCs in CRC patients.10
In our previously study, we found that the WEnCA plat-
form has a high sensitivity and specificity for detecting
activated KRAS expression in CRC patients.11 The WEnCA
platform requires many commercial kits so that whole ex-
periments can be performed, which is inconvenient and
requires much time to accomplish the test conditions of the
experiments. If the reagent kit is used exclusively for the
platform, the WEnCA could be easy to operate and could
increase stability. In this study, we used the GeneCling
Enzymatic Gene Chip Detection Kit (MedicoGene Biotech-
nology Corp., Los Angeles, LA, USA)da reagent kit specif-
ically developed for the WEnCA platformdto analyze the
gene expression of CTCs in the peripheral blood of CRC
patients. We also analyzed gene expression by using RT-
QPCR. We then determined the degree of consistency be-
tween the two methods.
Materials and methods
Patients and sample collection
Whole blood samples were collected from 30 colorectal
cancer patients who had undergone surgical resection.Each individual and/or their guardians provided written,
informed consent. The Kaohsiung Medical University Hos-
pital Institutional Review Board approved the sample
acquisition and its subsequent use. Clinical stages and
pathological features of the primary tumors were defined in
accordance with the criteria of the American Joint Com-
mission on Cancer (AJCC).
GenCling Enzymatic Gene Chip Detection Kit
Based on our previous study,12 we selected 31 candidate genes
that aremost closely related toCRC todevelop and construct a
gene chip. Oligonucleotide sequences were design by Vec-
torNTI software (Life Technologies Corp., Grand Island, NY,
USA). The newly synthesized oligonucleotide fragments were
dissolved in deionized distilled water and then blotted in trip
licate onNytran SuPerCharge nylonmembrane (Schleicher and
Schuell, Dassel,Germany).Dimethyl sulfoxide (DMSO)was also
dispensed onto the membrane as a blank control. After un-
dergoing rapid drying and crosslinking procedures, the prepa-
ration of the gene chip was complete. The gene chip was
analyzed by the GenCling Enzymatic Gene Chip Detection Kit
(MedicoGene Biotechnology Corp.) in accordance with the
manufacturer’s instructions. Total RNAwasextracted fromthe
peripheral blood of CRC patients. After performing comple-
mentary DNA (cDNA) synthesis and biotin labeling, the biotin-
labeled probes hybridized with the well-established oligonu-
cleotidechip. Thechip thenunderwent awashingandblocking
procedure, and subsequently reacted with streptavidin-alkyl
phosphatase. The chip was incubated in chromogen solution
containing nitroblue-tetrazolium and 5-bromo-4-chloro-3-
indolyl-phosphate (NBT/BCIP) while color developed. The hy-
bridized arrays were then scanned with the Epson Perfection
1670 flat bed scanner (Seiko Epson Corp., Nagano, Japan). Sub
sequentquantificationanalysis of each spot’s intensitywasper
formed by using AlphaEase FC software (Alpha Innotech Corp.,
SanLeandro,CA,USA). Spots consistently varyingbya factorof
two or more were considered as a differential expression.
Real-time quantitative PCR (RT-QPCR)
Real-time quantitative PCR was performed in a Rotor-Gene
2070 thermocycler (Corbett Research, Inc., Sydney,
Australia). The reaction mixture contained 2 mL of 20 mM
deoxyribonucleotide triphosphate (dNTP); 2 mL of 30 mM
magnesium chloride; 2mL of 20X SYBR green (Promega Corp,
Madison,WI,USA); 2mLof 1mM forwardprimer; 2mLof 1mM
reverse primer; 4 mL of nuclease free water; 2 mL of
80e100 ng/mL cDNA; and 2 mL of 1 U/mL polymerase. The
PCR conditions were as follows: 35 cycles of denaturation at
95 C for 20 seconds, annealing at 60 C for 20 seconds, and
extension at 74 C for 40 seconds. The PCR products [i.e.,
synthesized double-stranded DNA (dsDNA)] were quantified
Table 1 Clinicopathological features of 30 colorectal
cancer patients.
Characteristics Number of
cases (n Z 30)
%
Gender
Male 16 53.3
Female 14 46.7
Age (y)
<60 14 46.7
60 16 53.3
Tumor size (cm)
<5 17 56.7
5 13 43.3
Stage (AJCC)
I þ II 17 56.7
III 13 43.3
Vascular invasion
Negative 26 86.7
Positive 4 13.3
Perineural invasion
Negative 28 93.3
Positive 2 6.7
Serum CEA level
Abnormal 3 10.0
Normal 27 90.0
Liver metastasis
Yes 4 13.3
No 26 86.7
AJCC Z American Joint Committee on Cancer.
A
B
GCNThTERTKRT20HMGB1BIRC5KRT19
GCNThTERTKRT20HMGB1BIRC5KRT19
MMPCAP2BMI1CEACHRNB1PSAT1
PDXELAVL4DVL1CD55TMPOPSG2
GCNThTERTKRT20HMGB1BIRC5KRT19
MMPCAP2BMI1CEACHRNB1PSAT1
MMPCAP2BMI1CEACHRNB1PSAT1
PDXELAVL4DVL1CD55TMPOPSG2
PDXELAVL4DVL1CD55TMPOPSG2
Figure 1 The gene chip results. (A) The position of the oligonucl
genes, one housekeeping gene (b-actin), one plant gene (Oryza sati
of each image represent b-actin (i.e., the positive control) and th
plant gene (i.e., the negative control).
CRC enzymatic gene chip detection kit 89by measuring the fluorescent intensity at the end of each
amplification cycle. To ensure the reproducibility of results
of each sample, RT-QPCR analysis was repeated in three in-
dependent experiments.
Statistical analysis
All data were analyzed by using SPSS version 11.0 (SPSS,
Inc., Chicago, IL, USA). The c2 test was used to analyze the
detection of disseminated tumor cells in peripheral blood
by detection kit and the clinicopathological features. The
difference between data obtained by the detection kit and
by RT-QPCR was calculated by using linear regression and
by Pearson’s correlation. A p < 0.05 was considered sta-
tistically significant.
Results
Characteristics of patients
Thirty whole blood specimens were collected from CRC
patients. Sixteen men (55.3%) and 14 women (46.7%) were
recorded. The average age was 60.6 years (the age range
was 30e77 years). Table 1 shows the clinicopathological
characteristics of these 30 patients, who met the Interna-
tional Union Against Cancer (UICC) stage IeIII CRC criteria.
Differential expression profile of 31 CRC-related
gene in colorectal cancers
The gene expression of 30 CRC patients was analyzed by the
WEnCA platform with the GeneCling Enzymatic Gene Chip
Detection Kit (Fig. 1). Of the 31 CRC-related genes, nine
genesdDVL1, ELAVL4, CHRNB1, UBE2C, PSAT1, CEA,-actinOryza sativablankblankblankNPM11
-actinOryza sativablankblankblankNPM11
MUC1ENO2METMYCPTTG1OLFM413
PDE6DFOXM1UBE2CTK1CA9CTHRC11
-actinOryza sativablankblankblankNPM11
MUC1ENO2METMYCPTTG1OLFM413
MUC1ENO2METMYCPTTG1OLFM413
PDE6DFOXM1UBE2CTK1CA9CTHRC11
PDE6DFOXM1UBE2CTK1CA9CTHRC11
Positive control
Negative control
eotide probes on a nylon membrane array containing 31 target
va), and a blank control. (B) The spots within the red rectangle
e spots within the blue rectangle of each image represent the
Table 2 The overexpression rates of 31 target genes in 30
colorectal cancer patients, as assessed by the GeneCling
Enzymatic Gene Chip Detection Kit.
Genes Overexpression
(%)
DVL1, ELAVL4, UBE2C, PSAT1,
CHRNB1, CEA, PTTG1, KRT19,
hTERT
>90
PSG2, TMPO, PDX1, MMP13 70e90
OLFM4, CTHRC1, CA9, TK1, BMI1,
CAP2, MYC, ENO2, MUC1, HMGB1,
GCNT1, NPM1
50e70
CD55, FOXM1, PDE6D, MET, BIRC5,
KRT20
<50
90 C.-H. Wu et al.PTTG1, KRT19, and hTERTdwere overexpressed in more
than 90% of the CRC patients. Four genes were overex-
pressed in 70e90% of the patients, 12 genes were overex-
pressed in 50e70% of patients, and six genes wereFigure 2 The curves show (A) the quantitative polymerase
chain reaction (QPCR) result of 31 colorectal cancer (CRC)-
related genes in 30 CRC patients and (B) the linear regression
and correlation analyses for 930 paired measures of gene
expression by real-time QPCR (RT-QPCR) and by the GeneCling
Enzymatic Gene Chip Detection Kit for 31 markers in the pe-
ripheral blood of 30 CRC patients.overexpressed in <50% of patients (Table 2). These over-
expression rates are concordant with the data that were
analyzed by using the original WEnCA operating procedure.
However, the correlation between the 31 genes and the
clinicopathological features of CRC patients showed no
significant difference (data not shown).
Correlation between the GeneCling Enzymatic
Gene Chip Detection Kit and RT-QPCR
To understand the correlation between the GeneCling Enzy-
matic Gene Chip Detection Kit and RT-QPCR, we analyzed
gene expression by RT-QPCR. Using linear regression analysis,
the gene expression ratio of the detection kit was highly
consistent with RT-QPCR (rZ 0.901, p < 0.0001; Fig. 2).
Discussion
In the present study, we demonstrated the overexpression
pattern of 31 genes in CRC patients. Of the 31 genes, nine
genesdDVL1, ELAVL4, CHRNB1, UBE2C, PSAT1, CEA, PTTG1,
KRT19, and hTERTdhad an overexpression rate>90%. Three
genes (DVL1, ELAVL4, and CHRNB1) of the nine genes had
overexpression rates as high as 100%. The human homolog of
the Drosophila disheveled (DVL1) gene, which is involved in
Wnt pathway, is overexpressed in many cancers.13e15 Em-
bryonic lethal, abnormal vision, Drosophila-like 4 (ELAVL4),
an RNA binding protein, is associated with neuronal cell
maturation, malignant neuroblastoma, and Parkinson’s dis-
ease.16,17 The cholinergic receptor, nicotinic, beta 1
(CHRNB1) gene encodes the beta subunit of the acetylcho-
line receptor that changes conformation on acetylcholine
binding, leading to the opening of ion-conducting channel
through the plasma membrane. The correlation between
CHRNB1 and cancer is still unclear. However, because of the
small sample size analyzed in this study, there was no sig-
nificant correlation between the expression of the nine
genes and the clinicopathological features of the CRC pa-
tients. Therefore, more samples are needed for further
investigation to verify a clinical value.
Primary tumors can be detected the CTCs in the pe-
ripheral blood during the early stage of cancer.18 There-
fore, detecting CTCs in the peripheral blood could be a
noninvasive method for diagnosing CRC. Based on our pre-
vious studies, WEnCA analysis for detecting molecular
markers of CTCs has a very high sensitivity and specificity.
The detection limitation of WEnCA assay is 12 cancer cells
in 5 mL of blood.11 The WEnCA platform is a good method
for detecting CTCs in the peripheral blood of CRC patients.
In this study, the expression of 31 CRC-related genes was
analyzed by the GeneCling Enzymatic Gene Chip Detection
Kit, which was specifically developed for the WEnCA plat-
form. A high consistency existed between the detection kit
and RT-QPCR by comparing the gene expression ratio of
these two methods in 30 CRC patients. The GeneCling
Enzymatic Gene Chip Detection Kit comprises different
procedures such as RNA extraction, cDNA synthesis, hy-
bridization, washing and blocking, and color development
that involve various reagents. These tests are simple to use,
convenient, and fast, compared to previous methods that
use kits of different brands for each step and that require
CRC enzymatic gene chip detection kit 91individual adjustments to obtain optimal reaction condi-
tions. With standard procedures and conditions for re-
actions, operating the WEnCA platform could become even
more stable.
The overall use of the GeneCling Enzymatic Gene Chip
Detection Kit for WEnCA platform analysis is easy, conve-
nient, and fairly stable. The pattern of gene expression can
be understood by current analysis. Analysis of more samples
is needed to explore the correlation between genetic dif-
ferences and patients’ clinicopathological features.
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